Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 23 September 2027
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC